Pioneers in the development
of personalized immunotherapy

Founded on the belief that immunotherapy made from a patient’s own cells will transform cancer treatment, Dendreon is fighting for patients by making the battle against cancer personal. By harnessing the power of the body’s immune system, we help extend the lives of patients battling cancer.

Our flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Since its approval in 2010, nearly 30,000 men with advanced prostate cancer have been prescribed PROVENGE. Today, we continue to push our research forward so that we may help even more patients fight cancer with personalized immunotherapy.

Our Commitment

In the fight against cancer, our patients aren’t giving up, and neither are we. We aim to extend life without reducing quality of life. This commitment — to patients, families, and the physicians who treat them — drives all that we do.

Dedicated to Patients

Making the fight against cancer personal, with immunotherapy created from a patient’s own immune cells

Providing immunotherapy treatments that are clinically proven to help extend life, with a generally well tolerated safety profile

Offering services and support that improve treatment access

Supporting Clinical Practices

Partnering with physicians, nurses, and clinicians as they continue to realize the full potential of immunotherapy

Helping urologists identify patients who will get the most out of immunotherapy

Focused on the Future

Expanding access to PROVENGE for more patients, in the United States and around the world

Investigating earlier-stage treatment of prostate cancer with PROVENGE, with the goal of helping even more patients

Exploring the use of personalized immunotherapy to treat other cancer types

Our History

1992
  • Inspired by their research at Stanford School of Medicine, Edgar Engleman and Samuel Strober establish Activated Cell Therapy.

1993
  • Activated Cell Therapy opens its first R&D facility.

1995
  • The Antigen Delivery Cassette is developed, which will become the basis of the Active Cellular Immunotherapy platform.

1997
  • Activated Cell Therapy changes its name to Dendreon.

1999
  • Dendreon moves its headquarters to Seattle, Washington.

2000
  • Dendreon enters the NASDAQ with an IPO of $45 million to fund trials and preclinical activities for therapeutic cancer vaccines.

2001
  • Dendreon is awarded a US patent (No. 6,210,662) for the composition of sipuleucel-T.

2003
  • Phase III IMPACT study evaluating sipuleucel-T in men with advanced prostate cancer begins.

  • Study results eventually serve as the basis for US Food and Drug Administration (FDA) approval.

2006
  • Dendreon completes Biologics License Application (BLA) submission to the FDA — the first BLA for an active cellular immunotherapy for cancer.

2007
  • The FDA’s Advisory Committee votes in favor of the safety and efficacy of PROVENGE, advancing sipuleucel-T toward FDA approval.

  • Patients and advocates rally for PROVENGE after the FDA requests additional efficacy data.

2009
  • Dendreon completes Phase III IMPACT clinical trial and reports positive topline results.

2010
  • Dendreon receives FDA approval for sipuleucel-T (PROVENGE), the first FDA-approved immunotherapy made from a patient’s own immune cells.

  • Commercial manufacturing of PROVENGE begins in Morris Plains, New Jersey.

  • The New England Journal of Medicine publishes results of the IMPACT trial demonstrating that PROVENGE extends median overall survival for men with advanced prostate cancer by 4.1 months.

2011
  • The FDA approves PROVENGE manufacturing sites in Seal Beach, California and Union City, Georgia.

2013
  • More than 10,000 men prescribed PROVENGE.

2014
  • The National Comprehensive Cancer Network (NCCN) recommends PROVENGE for first-line use in patients with M1 CRPC.

2015
  • Valeant Pharmaceuticals acquires Dendreon for $495 million.

  • More than 20,000 men prescribed PROVENGE.

2016
  • Dendreon delivers first profitable year since its inception.

2017
  • Dendreon resumes operations as a standalone company following acquisition by Sanpower Group for $819.9 million.

  • Dendreon reports its most profitable year in the company’s history.

2018
  • Over 30,000 men prescribed PROVENGE.

Our Management Team

Our leadership offers unparalleled experience in the biotechnology and pharmaceutical industries. Together, we are leading the charge to develop, manufacture, and commercialize immunotherapies that will continue to revolutionize cancer treatment.

Learn more about the people shaping the future of cancer treatment.

Jim Caggiano

Chief Executive Officer


Read Bio

do not edit

A seasoned and dynamic leader with a proven track record of creating significant value in turnaround situations, Mr. Caggiano has nearly 30 years of experience in the biotechnology, pharmaceutical and medical device marketplaces.

Under Mr. Caggiano’s leadership, Dendreon has been transformed into an exciting and growing enterprise that is making the fight against cancer personal by harnessing the power of the body’s immune system to fight back.

Matt Kemp

Chief Commercial Officer


Read Bio

do not edit

A highly experienced healthcare executive, Mr. Kemp has nearly 20 years of leadership experience across marketing and commercial operations in the pharmaceutical, biotech and medical device industries. A strategic leader with a proven track record of achieving results through effective commercial strategies, he has held positions of increasing responsibility at leading healthcare organizations.

At Dendreon, Mr. Kemp is a member of the Executive Committee and is responsible for all aspects of sales and marketing for the company’s flagship product, PROVENGE.

Christina Yi

Chief Operations Officer


Read Bio

do not edit

An adaptive and principles-driven operations leader, Ms Yi offers 20 years of experience and a proven track record of success across various aspects of pharmaceutical operations. Leveraging modern operational approaches and data to deliver consistent, high-impact results, Ms. Yi has successfully brought innovative products to market through strategic planning, efficient process design and regulatory compliance. Her career is marked by an ability to lead, develop, and execute product strategies and programs that drive and deliver measurable business results.

A member of the Executive Committee, Ms. Yi is responsible for manufacturing, quality, sourcing and procurement, technical operations, apheresis operations and project management at Dendreon.

Chris Carr

Chief Financial Officer


Read Bio

do not edit

A high-impact and strategic leader, Mr. Carr has over 25 years of financial experience in the pharmaceutical and biotech industries. Balancing professional curiosity with operating humility, he has a demonstrated track record of building financial infrastructures that enhance efficiency. A trusted business partner demonstrating strong communication, financial analysis and business process improvement skills, he has extensive experience working in a variety of executive, managerial and project management roles.

As a member of the Executive Committee, Mr. Carr’s tenacious approach aims to simplify and optimize Dendreon’s finance, audit, treasury and information systems to meet organizational goals.

Kevin Helmbacher

General Counsel, Senior Vice President, Legal and Compliance


Read Bio

do not edit

A versatile and talented pharmaceutical attorney, Mr. Helmbacher has over 20 years of legal and compliance experience in the pharmaceutical and biotechnology industries. Over the course of his career, he’s demonstrated success by providing results-oriented, high-quality legal and compliance counsel on a wide range of legal matters encountered by life science companies, such as healthcare law, FDA compliance, transactions, intellectual property and general business law.

As a member of the Executive Committee, Mr. Helmbacher is responsible for leading all aspects of the legal and compliance functions at Dendreon.

Beth S. Mueller

Senior Vice President, Human Resources


Read Bio

do not edit

With over 20 years of experience in human resources, Ms. Mueller is a dynamic, energetic and results-oriented leader. Her depth of experience covers all aspects of human resources, including organizational development, talent acquisition, and total rewards in the pharmaceutical and biotechnology industries. She has proven expertise in both the corporate and private sector, supported by her strong history of achievement spanning several leadership roles. Ms. Mueller has demonstrated her positive impact and success in working with all levels of an organization and is respected as a trusted, confidential business partner.

As a member of the Executive Committee, Ms. Mueller is responsible for creating a best-in-class human resource function, building a strong HR team, coupled with developing and implementing the strategic vision to best meet organization goals and positively impact the culture of Dendreon.

Bruce Brown

Senior Vice President, Medical


Read Bio

do not edit

Having spent more than 20 years as a board-certified urologist, Dr. Brown is driven by the promise of improving the lives of men living with prostate cancer. Having bridged the gap between community practice and leading medical strategy for major pharmaceutical companies, Dr. Brown has a firm grasp on how achievements in drug discovery can translate into improved patient outcomes in real-world settings.

As a member of the Executive Committee, Dr. Brown is responsible for leading the company’s Medical organization, including research and manufacturing sciences, medical affairs, and regulatory affairs with an emphasis on expanding access to the company’s flagship immunotherapy treatment.

Board of Directors

Fang Xu


Read Bio

Jiangyong (Phillip) Bu


Read Bio

do not edit

Senior VP of Sanpower Group, Chairman of Biomedicine Industry Group and Chairman of Health & Senior Care Industry Group, Mr. Bu has rich experience in genomic testing, cellular immune therapy, hospital management, and senior care solutions. Mr. Bu deeply understands investment, financing, portfolio management, and capital exit. Under his leadership, multiple M&A deals (domestic and cross-border) have been executed successfully.

Prior to his current positions, Mr. Bu was CEO and Founder of the Shanghai Shengda Auto Service Company and was General Manager at Shanghai Yolo Electrical Appliances Co., Ltd. Mr. Bu holds an EMBA from China Europe International Business School (CEIBS).

Yang Wang


Read Bio

do not edit

Non-Executive Director and Vice President of Sanpower Group, Ms. Wang is responsible for cross-border investment execution. Ms. Wang was formerly an investment banker at Citigroup Global Markets Limited and Barclays Capital Inc. Prior to that, she worked at the World Bank’s International Finance Corporation (IFC) and advised on equity investments in China. Ms. Wang received a master’s in finance from Peking University and an MBA from the Wharton School at the University of Pennsylvania.

Yuzhou (Donald) Wang


Read Bio

do not edit

Mr. Wang has over 15 years of experience in international finance, audit, consulting, and corporate financial management, and has worked on numerous IPOs, restructure projects, and cross-border mergers and acquisitions. He is a member of the Chinese Institute of Certified Public Accountants, the China Certified Tax Agents Association, the Association of Chartered Certified Accountants, and the Institute of Certified Internal Auditors.

Prior to his current position at Sanpower Group, Mr. Wang served as the finance VP of Zenix Auto International (NYSE: ZX), where he facilitated the NYSE IPO process and managed the company’s daily financial work and M&A projects. He also previously worked at PWC in Transaction Services and at Deloitte in Audit. Mr. Wang holds a bachelor’s degree in Business Administration from Fudan University and is fluent in English.

Michael Steven Weiss


Read Bio

Chris Carr


Read Bio

do not edit

A high-impact and strategic leader, Mr. Carr has over 25 years of financial experience in the pharmaceutical and biotech industries. Balancing professional curiosity with operating humility, he has a demonstrated track record of building financial infrastructures that enhance efficiency. A trusted business partner demonstrating strong communication, financial analysis and business process improvement skills, he has extensive experience working in a variety of executive, managerial and project management roles.

As a member of the Executive Committee, Mr. Carr’s tenacious approach aims to simplify and optimize Dendreon’s finance, audit, treasury and information systems to meet organizational goals.

Jim Caggiano


Read Bio

do not edit

A seasoned and dynamic leader with a proven track record of creating significant value in turnaround situations, Mr. Caggiano has nearly 30 years of experience in the biotechnology, pharmaceutical and medical device marketplaces.

Under Mr. Caggiano’s leadership, Dendreon has been transformed into an exciting and growing enterprise that is making the fight against cancer personal by harnessing the power of the body’s immune system to fight back.

Corporate Governance

Our patients, their families, and the physicians who treat them are counting on us to conduct business with honesty and integrity. We value our relationship with our employees, partners, contractors, vendors, and the communities in which we operate and hold ourselves to a high ethical standard. Dendreon follows all relevant laws, regulations, guidelines, and codes concerning the pharmaceutical industry.

Our Science

Our research led the way in making personalized immunotherapy a reality.

Learn More

important safety information